Edison Investment Research - AUSTRIACARD HOLDINGS AG (ACAG) AUSTRIACARD - Acquiring data analytics expertise

Report

Edison Investment Research

Richard Williamson

AUSTRIACARD - Acquiring data analytics expertise

AUSTRIACARD has acquired a UK-based specialist in data analytics for €1.6m. This should bolster the group’s digital transformation technologies (DTT) practice and provide a route for LSTech to commercialise its technology. As LSTech is focused on similar verticals as AUSTRIACARD’s DTT business, the deal provides the potential for cross-selling as well as the enhancement of existing AUSTRIACARD solutions.

21/05/2024 1 EN

Underlying

AUSTRIACARD HOLDINGS AG

See profile

AT0000A325L0 Austria

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Williamson

Other Reports on these Companies

Edison Investment Research

AUSTRIACARD - Outlook points to H2-weighted growth

AUSTRIACARD reported adjusted revenue growth of 1.4% for Q124, reflecting comparison to a particularly strong Q123. Better sales mix and good control over the cost base resulted in expansion of the adjusted EBITDA margin to 15.2% (+0.1pp y-o-y). Contracts signed in all three business areas should drive revenue acceleration from Q2, providing support for management’s target of 10% growth in adjusted revenue in FY24. We revise our forecasts to reflect management guidance, higher working capital and the recent LSTech acquisition, resulting in small reductions in our EPS forecasts.

June 5, 2024 June 5, 2024 1 EN

Eurobank Equities

AUSTRIACARD HOLDINGS | Growth story still on course; valuation gap remains

Healthy Q1’24 on tough comps, 2024e guidance underpins 2-digit growth story – Austriacard reported healthy Q1’24 results, growing adj. revenues 1.4% yoy (to €89.7m) and adj. EBITDA +2.2% yoy (to €13.7m) on tough comps. Although Q1 growth may look tepid, management provided a confident 2-digit growth outlook for the full year (revenues +10%, adj. EBITDA 10-12%) indicating back-loaded growth fueled by the phasing of recently signed contracts. The 2024 guidance effectively validates the 2-digit growth story articulated in our initiation report, with ACAG being well placed to benefit from structur...

June 5, 2024 June 5, 2024 1 EN

BB Biotech - Positive trial news lifts two portfolio holdings

In our last BB Biotech (BION) review note, published in May 2024, we noted that the biotech sector was eagerly awaiting some key milestones, the most important being Alnylam Pharmaceuticals’ late-stage clinical trial of vutrisiran for patients with ATTR cardiomyopathy, a deadly heart disease. Alnylam, which comprised 4.3% of BION’s portfolio at end March 2024, released very positive, statistically significant, Phase III trial results this week. Assuming regulatory clearance, Alnylam expects that vutrisiran has the potential to become the new standard of care for the treatment of this disease, ...

8h / 8m 8h / 8m 1 EN

Martyn King

Martyn King

Phoenix Spree Deutschland - Accelerating the unlocking of value

While the Berlin private rental market continues to be strong, Phoenix Spree Deutschland (PSD) has adapted its historical rent reversion strategy to the changes in market conditions. It plans a material increase in condominium sales, intended to accelerate the unlocking of value embedded in the portfolio, reduce borrowings and better position the company for refinancing in 2026. In this report we analyse in detail the potential impacts of this strategy on earnings, NAV and gearing, but, given the variables involved, refrain from forecasting the outcomes precisely.

11h / 25m 11h / 25m 1 EN

Sean Conroy

Sean Conroy

Newron Pharmaceuticals - Evenamide road to registration and beyond

Newron hosted an investor day (25 June) featuring three key opinion leaders (KOLs) who highlighted evenamide’s unique mechanism at the site of pathology, offering durable responses and addressing unmet need despite the >40 available treatments for schizophrenia. Evenamide has a robust track record in clinical studies to date. Notably, the results of study 015 in treatment-resistant schizophrenia (TRS) saw 25% of patients achieve remission, and, more recently, the results from study 008A (poorly managed schizophrenia) confirmed the safety of evenamide as an add-on to current antipsychotics, as ...

12h / 20m 12h / 20m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

AUSTRIACARD - Acquiring data analytics expertise

AUSTRIACARD - Outlook points to H2-weighted growth

AUSTRIACARD HOLDINGS | Growth story still on course; valuation gap remains

BB Biotech - Positive trial news lifts two portfolio holdings

Phoenix Spree Deutschland - Accelerating the unlocking of value

Newron Pharmaceuticals - Evenamide road to registration and beyond

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe